These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31642413)

  • 1. MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present).
    Rusiecki R; Witkowski J; Jaszczewska-Adamczak J
    Recent Pat Anticancer Drug Discov; 2019; 14(4):324-369. PubMed ID: 31642413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
    Weber L
    Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018).
    Skalniak L; Surmiak E; Holak TA
    Expert Opin Ther Pat; 2019 Mar; 29(3):151-170. PubMed ID: 30822185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).
    Zak K; Pecak A; Rys B; Wladyka B; Dömling A; Weber L; Holak TA; Dubin G
    Expert Opin Ther Pat; 2013 Apr; 23(4):425-48. PubMed ID: 23374098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
    Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53-Mdm2 inhibitors: patent review (2009 - 2010).
    Kamal A; Mohammed AA; Shaik TB
    Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
    Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
    Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
    Shangary S; Wang S
    Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
    Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
    Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
    Haronikova L; Bonczek O; Zatloukalova P; Kokas-Zavadil F; Kucerikova M; Coates PJ; Fahraeus R; Vojtesek B
    Cell Mol Biol Lett; 2021 Dec; 26(1):53. PubMed ID: 34911439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
    Dickens MP; Fitzgerald R; Fischer PM
    Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer.
    Bhatia N; Khator R; Kulkarni S; Singh Y; Kumar P; Thareja S
    Curr Med Chem; 2023; 30(32):3668-3701. PubMed ID: 37190755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
    Millard M; Pathania D; Grande F; Xu S; Neamati N
    Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.
    Teveroni E; Lucà R; Pellegrino M; Ciolli G; Pontecorvi A; Moretti F
    Expert Opin Ther Pat; 2016 Dec; 26(12):1417-1429. PubMed ID: 27603098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.